Stevens Capital Management’s Pacific Biosciences PACB Stock Holding History

Stevens Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,370	Closed	-$75K	–	718
2019 Q2	$75K	Sell	12,370 -52,450	-81%	-$368K	﹤0.01%	602
2019 Q1	$469K	Sell	64,820 -269,783	-81%	-$1.95M	0.02%	501
2018 Q4	$2.48M	Buy	+334,603	New	+$2.12M	0.13%	227
2016 Q3	–	Sell	-14,801	Closed	-$104K	–	1078
2016 Q2	$104K	Buy	+14,801	New	+$135K	﹤0.01%	829
2014 Q2	–	Sell	-43,858	Closed	-$235K	–	1245
2014 Q1	$235K	Buy	43,858 +31,944	+268%	+$202K	0.01%	874
2013 Q4	$62K	Buy	+11,914	New	+$54.7K	﹤0.01%	978

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

KLCMU

Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Stevens Capital Management's PACB Position: Q3 2019 in Review

Stevens Capital Management sold out of Pacific Biosciences (PACB) in Q3 2019, closing a stake of 12,370 shares — an estimated $75K sold.

Stevens Capital Management first reported a position in PACB in Q4 2013 and held it in 6 quarters. The position peaked at $2.48M in Q4 2018. 148 funds tracked by Wall St. Rank hold PACB as of Q3 2019.

Stevens Capital Management reported no remaining Pacific Biosciences position as of Q3 2019 after selling out during the quarter.
Stevens Capital Management sold 12,370 Pacific Biosciences shares in Q3 2019, an estimated $75K.
Stevens Capital Management first reported a position in Pacific Biosciences in Q4 2013 and held it in 6 quarters.
Stevens Capital Management's Pacific Biosciences position peaked at $2.48M in Q4 2018.
148 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2019.

Based on Stevens Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.